key: cord-0685516-ee3r4cdq authors: Querido, Sara; Calça, Rita; Weigert, André; Francisco, Diogo; Adragão, Teresa; Ana Pessanha, Maria; Gomes, Perpétua; Rodrigues, Luís; Figueira, João M.; Cardoso, Conceição; Machado, Domingos title: Kinetics of torquetenovirus DNA load in a recent kidney transplant recipient with mild SARS‐CoV‐2 infection and a failed antibody response date: 2020-12-06 journal: Transpl Infect Dis DOI: 10.1111/tid.13524 sha: cbd993adc31a01050f64fab78429646031826914 doc_id: 685516 cord_uid: ee3r4cdq Kidney transplant (KT) recipients are at an increased risk for severe COVID‐19 because of their immunosuppressed state. A 42‐year‐old KT patient was diagnosed with COVID‐19 three months after KT. Despite lymphopenia and several risk factors, he had a mild disease course. Nasopharyngeal real‐time reverse transcriptase polymerase chain reaction for SARS‐CoV‐2 became negative 48 days after detection. SARS‑CoV‑2 IgG antibodies became negative after day 40. TTV DNA load increased with the onset COVID‐19 and reduced after its resolution. This is the first report where TTV DNA load was measured during the course of COVID‐19. in January 26, 2020. Obesity and hypertension were additional comorbidities. Immunosuppression included thymoglobulin, tacrolimus, mycophenolate mofetil (MMF), and prednisolone. Hemodialysis was required for 2 weeks after KT because of delayed graft function. Kidney function gradually improved and his eGFR (CKD-EPI) at discharge was 36 mL/min/1.73 m 2 . On April 25, 2020 (day 0) he was admitted for elective removal of ureteral stent. He complained of low-grade fever and mild thoracic pain 3 days prior to admission. He denied dyspnea, cough, or gastrointestinal symptoms. Physical evaluation was unremarkable: body temperature was 36.5ºC and oxygen saturation was 98% in ambient air, blood pressure was 110/69 mmHg and respiratory rate was 25 breaths per minute. Real-time reverse transcriptase polymerase chain reaction (RT-PCR) nasopharyngeal swab for SARS-CoV-2, routinely performed 24 hours before surgical procedures, unveiled a positive result. Laboratory results revealed lymphopenia, slightly elevated C-reactive protein and D-dimer, stable kidney function ( Figure 1 ) and normal levels of transaminases, lactic dehydrogenase, and ferritin. Tacrolimus through blood level of tacrolimus was 10.6 ng/mL. Arterial blood gas exam and chest X-ray were normal. He was admitted to a COVID-19 specific ward. On admission, tacrolimus dose was reduced, prednisolone was increased to 20 mg/ day and MMF was suspended. On day 2, TTV viral load was 7.14log 10 , serum Immunoglobulin G (IgG) and Immunoglobulin M (IgM) were decreased and CD4+, CD8+, CD3+, and CD 19 + count in peripheral blood were reduced ( Figure 1 ). Cytomegalovirus (CMV), BK virus (BKV), and JC virus (JCV) viremia were absent. During admission, he remained asymptomatic with stable renal function but with persistent leucopenia and lymphopenia. No antimicrobial or antiviral therapies were prescribed. He was discharged at day 7. After discharge, lymphopenia, IgG, and IgM levels progressively RT-PCR SARS-CoV-2 became negative on day 48 and day 50, when he was considered cured. Kinetics of TTV DNA load was stable during COVID-19 (7.14 log 10 -7.87 log 10 ), however, 2log 10 higher than TTV viral load at month 1 and at month 6 after KT (5.6 log 10 and 5.9 log 10 , respectively) ( Figure 2 ). We present a patient infected with SARS-CoV-2 3 months after a KT. Despite several risk factors for severe COVID-19 (immunosuppression, diabetes, hypertension, and obesity) and biomarkers associated with poor outcomes (neutropenia, lymphopenia, elevated levels of C-reactive protein and D-dimer), he had a mild disease course. Lymphocyte subpopulations were also reduced, consistent with an immunosuppressed status. Lymphopenia is a common feature in patients with COVID-19 and may be a critical factor associated with disease severity and mortality. 11 In the setting of transplantation, lymphopenia may be multifactorial. As many KT patients have pre-existing lymphocyte depletion, further drop in lymphocyte may be more meaningful as a prognostic marker. 12 In our patient, lymphopenia was present before COVID-19, because of thymoglobulin induction and maintenance immunosuppression. Nevertheless, lymphocytes significantly decreased between D2 and D7, with subsequent partial recovery. At admission, the dose of prednisolone was increased from 5 mg to 20 mg/day, with progressive tapering. Steroid increment may be justified to reduce the risk of acute rejection, suppress the inflammatory cascade and reduce mortality. 15 However, the additional risk of opportunistic infections needs to be weighed. In this case, despite adjustment in immunosuppression, kidney function remained stable without evidence of rejection. In non-immunosuppressed patients, age is the main contributor to disease severity and outcome, 16 so this could be one of the reasons for the mild course of disease in this case. In general population with COVID-19, the median duration of virus shedding is 20 days. 17 However, in solid organ transplant recipients viral shedding could last longer, up to 68 days. 14,17 Our patient presented viral shedding for 48 days after diagnosis. Immunosuppression may impair viral clearance, 18 leading to a prolonged viral shedding. Data on antibody response in transplant patients are scarce. In a recent report, 19 a KT patient who developed COVID-19 pneumonia less than one month after KT, did not develop IgM/IgG antibodies for more than 2 months. In our report, SARS-CoV-2 total Ab were sustainably negative, probably because of an inability of suppressed naïve T cells to recognize viral antigens, contributing to absent response of specific humoral immunity. 20 However, IgG antibodies were marginally positive but became negative after day 40. Possible explanations include false positivity or viral-induced clonal deletion. Reduced total IgM levels, borderline low IgG levels and reduced CD19 + lymphocytes during COVID-19, reveal an impaired humoral immunity, which could contribute to the inability to produce a specific antibody response against SARS-CoV-2. Until now, no reliable marker has been identified to quantify the net state of immunosuppression in transplant patients. Kinetics of TTV DNA load has gained attention and have made this virus a possible marker of immune function, able to predict the risk of graft rejection and infection after KT. 10 It is expected that TTV viral load increases from day 7 do day 30 after KT, peaks around month 3 to 12 post-KT and reaches steady state thereafter. 21 In a recent study, 21 F I G U R E 2 TTV: torquetenovirus; Ab: antibodies; SARS-CoV-2: Severe acute respiratory syndrome Coronavirus 2; IgG: immunoglobulin G; RNA: ribonucleic acid. Total Ab SARS-CoV-2 -Electrochemiluminescence immunoassay for qualitative in vitro detection of total antibodies (IgM and IgG) against SARS-CoV-2 (Elecsys Anti-SARS-CoV-2 total Ab, Cobas e602); negative < 1. IgG SARS-CoV-2 -Chemiluminescence microparticle immunoassay for qualitative detection of IgG antibodies against SARS-CoV-2 (SARS-CoV-2 IgG, ARCHITECT i System); negative < 1.4 TTV DNA loads above 3.15 log 10 and 4.56 log 10 copies/mL at month 1 predicted the occurrence of post-transplant infection (adjusted hazard ratio [aHR]: 2.88; 95% confidence interval [CI]: 1.13-7.36; Pvalue = .027). In another study including 386 KT patients, 22 TTV viral load was higher at the end of month 3 post-transplant and reached steady state thereafter. Authors defined a TTV load between 1 × 10 6 and 1 × 10 8 copies/mL as the optimal range to minimize the risk for rejection and infection. Our patient was included in a prospective cohort study where TTV levels are measured at KT time, 1 week, 1 month and 3 months after KT and then quarterly until the first year post-KT. Coincidently, COVID-19 was diagnosed at the third month after KT. TTV DNA load was stable during COVID-19 (7.14log 10 -7.87 log 10 ), but higher than the TTV DNA load at month 1 and at month 6 after KT (5.6 log 10 and 5.9 log 10 , respectively). This increase in 2log 10 Considering the optimal range of TTV viral load, between 6 log 10 and 8 log 10 , the risk of organ rejection or severe infection during this period was accordingly minimized in this patient, in line with the good outcome of SARS-CoV-2 infection. This is the first report where the kinetics of TTV DNA load was measured during COVID-19. Further studies are needed to describe the kinetics of TTV viral load as a marker of immune function in KT patients infected with SARS-CoV-2, as well as in the general population. None. The authors received no financial support for the research, authorship, and/or publication of this article. S. Querido: concept/design, research study, data collection, data analysis, bibliographic review, drafting article; R. Calça and D. Clinical features of patients infected with 2019 novel coronavirus in Wuhan Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens Detection of antibodies against SARS-CoV-2 in patients with COVID-19 COVID-19 outcomes in patients waitlisted for kidney transplantation and kidney transplant recipients COVID-19 outcomes among solid organ transplant recipients: a case-control study COVID-19 infection in kidney transplant recipients: disease incidence and clinical outcomes COVID-19: consider cytokine storm syndromes and immunosuppression Coronaviruses and immunosuppressed patients: the facts during the third epidemic Torque-teno virus viral load as a potential endogenous marker of immune function in solid organ transplantation A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster COVID-19 infection in kidney transplant recipients COVID-19: implications for immunosuppression in kidney disease and transplantation COVID-19 in recent kidney transplant recipients Covid-19: low dose steroid cuts death in ventilated patients by one third, trial finds Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 xases from the Chinese center for disease control and prevention Viral shedding prolongation in a kidney transplant patient with COVID-19 pneumonia novel coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve Failed antibody response in a renal transplant recipient with SARS-CoV-2 infected Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy Monitoring of alphatorquevirus DNA levels for the prediction of immunosuppression-related complications after kidney transplantation Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients-A prospective observational trial Kinetics of torquetenovirus DNA load in a recent kidney transplant recipient with mild SARS-CoV-2 infection and a failed antibody response